Connectome Raises $2M to Make Brain Health Measurable Over Time

We track our steps, sleep, calories, heart rate variability, blood oxygen, and even how long we spent in REM last night. The average smartphone user generates more health data in a week than a 1990s hospital did in a year. But there is one organ we systematically ignore: the brain.

The paradox is striking. Physical health tracking has become cheap, continuous, and ubiquitous. A $40 smart ring tells you more about your cardiovascular system than a hospital stress test from a decade ago. Cognitive health, the single most valuable asset for knowledge workers, executives, and ageing populations, still relies on the equivalent of a Polaroid snapshot: a 30-minute test in a clinic that measures how you perform at exactly 2 PM on a Tuesday.

The startup, founded in 2024 by neuroscientists Lucas Scherdel and Dr Rufus Mitchell-Heggs, is trying to close that gap. The company uses functional near-infrared spectroscopy (fNIRS) — a non-invasive imaging technique — combined with machine learning to measure brain activity repeatedly and build personalised cognitive baselines. The key insight from Imperial College's LUCID study: brain blood flow patterns shift predictably based on sleep quality, stress, caffeine intake, and workload. A single measurement is noise. A thousand measurements are a signal.

The missing baseline

Traditional cognitive assessments, the kind used by neurologists and clinical trials, measure performance at a single point in time. Cambridge Brain Sciences and Lumosity-style tests capture a score and compare it against population averages. The problem, as Mitchell-Heggs explains, is that healthy brain function operates within a specific zone for each individual. Drift outside that zone signals potential decline. But without a personal baseline, you cannot tell whether a given score is normal for that person or the beginning of deterioration.

"Over 70% of cognitive decline occurs without noticeable symptoms before traditional diagnostics would intervene," Scherdel told TechFundingNews. "One in three people will experience a neurological or mental health condition in their lifetime."

Its approach is to measure each person repeatedly across different times of day, states of fatigue, and contexts until a stable baseline emerges. The platform then flags deviations: a drop in processing speed after a poor night's sleep is expected; a sustained decline over weeks is not. This is the same logic that makes continuous glucose monitors useful for non-diabetics: what matters is the trend, not the absolute number.

The company has already published its clinical measurement framework, built on research from Imperial's LUCID longitudinal study, and is rolling out its product with select partners in the performance and wellness sector. An elite football club is already trialling the platform with its players, tracking cognitive readiness across training cycles and travel schedules. The team's sports science unit declined to name the club.

The convergence of two curves

Connectome sits at the intersection of two accelerating trends. The first is the surge in neurotechnology investment. According to New Market Pitch's analysis of 22 disclosed deals between July 2025 and June 2026, the sector raised $1.56 billion, with brain-computer interfaces dominating at $955 million across 9 deals. The second is the mainstreaming of cognitive health as a workplace concern. Burnout, brain fog, and attention deficits have moved from clinical journals to boardroom discussions. Companies are increasingly treating cognitive capacity as an operational metric, not a personal health issue.

As we wrote earlier , whole-brain emulation crossed a fundamental threshold when Eon Systems demonstrated the first fruit fly brain driving a virtual body through its native connectome using no reinforcement learning or training, just biological wiring executing behaviour. That was proof that neural circuit dynamics can be captured, simulated, and embodied. The startup is working at a different scale, human and non-invasive and longitudinal, but the underlying premise is the same: brain function is not random, and with enough data it becomes predictable.

Why this round matters

The pre-seed round was led by Redstone, with Concept Ventures and Octopus participating, plus $120,000 in non-dilutive public innovation funding. For a company that has not yet launched a commercial product, the investor signal is instructive: Redstone and Concept Ventures are early-stage specialists who bet on platform infrastructure, not feature startups. The presence of Octopus, a firm more associated with climate tech than neurotech, suggests cognitive health monitoring is being seen as horizontal infrastructure rather than a narrow medical play.

The $2 million is modest relative to the $71 million average neurotech round. But the company does not need massive capital for hardware. It uses off-the-shelf fNIRS sensors and builds value in the software layer: the AI models that separate signal from noise, the baselining algorithms, and the contextual integration with sleep and activity data. This is a software-defined neurotech company, not a device company.

What happens to the neurotech market a year from now?

Development scenarios

Sources